II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Total Other Income Expenses Net

Last Annual Value

2.75M

3-Year CAGR

9%

5-Year CAGR

60%

10-Year CAGR

58%

II

ImageneBio Inc Competitors Analysis of Total Other Income Expenses Net

IMA · NASDAQ
CompanyTotal Other Income Expenses Net
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
2.75M
-27.1%160.4%N/A 
544.00K
-43.6%7.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
5.31M
-17.3%N/AN/A
-22.07M
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
6.06M
2.6%N/A35.2%
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-3.79M
N/AN/AN/A
2.96M
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-1.27M
N/AN/AN/A
-86.23M
N/AN/AN/A
25.02M
53.3%N/A70.5%
2.71M
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69